TriangleNCT00021255 · CITED IN SOURCE DOCUMENTS
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2016-11-15
Primary objective: * Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin. Secondary objective: * Compare overall survival of participants treated with these regimens. * Compare the toxic effects (including cardiac) of these regimens in these participants. * Compare quality of life of participants treated with these regimens. * Compare pathologic and molecular markers for predicting efficacy of these regimens in these participants. * For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with fluorescence in situ hybridization in predicting outcome in participants treated with these regimens.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With Disease Free Survival at 5 Years
Percentage of Participants With Disease Free Survival at 10 Years
Overall Survival- Percentage of Participants Who Survived at 10 Years
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion criteria: * Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the participants for treatment and follow-up. * Accessible for treatment and follow-up at participating centers. * Histologically proven breast cancer with an interval between definitive surgery that included axillary lymph node involvement assessment and registration of less than or equal to 60 days. A central pathology review might be performed post randomization for confirmation of diagnosis and molecular studies. The same block used for HER2neu determination prior to randomization might be used for the central pathology review. * Definitive surgical treatment must be either mastectomy with axillary lymph node involvement assessment, or breast conserving surgery with axillary lymph node involvement assessment for operable breast cancer (T1-3, Clinical N0-1, M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and/or ductal carcinoma in situ (DCIS). * Participants must be either lymph node positive or high risk node negative. Lymph node positive participants were to be defined as participants having invasive adenocarcinoma with at least one axillary lymph node (pN1) showing evidence of tumor among a minimum of six resected lymph nodes. High risk lymph node negative participants were to be defined as participants having invasive adenocarcinoma with either 0 (pNo) among a minimum of 6 resected lymph nodes or negative sentinel node biopsy (pNo) and at least one of the following factors: tumor size \> 2 cm, estrogen receptor (ER) and/or progesteron receptor (PR) status was negative, histologic and/or nuclear grade 2-3, or age \< 35 years. * Tumor must show the presence of the HER2neu gene amplification by Fluorescence In-Situ Hybridization (FISH analysis) by a designated central laboratory. * Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization. * Karnofsky Performance status index ≥ 80%. * Normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF) (multiple-gated acquisition \[MUGA\] scan) and electrocardiogram (ECG) within 3 months prior to registration. The result of the MUGA must be equal to or above the lower limit of normal for the institution. * Laboratory requirements: (within 14 days prior to registration) a) Hematology: i) Neutrophils ≥ 2.0 109/L ii) Platelets ≥ 100 109/L iii) Hemoglobin ≥ 10 g/Dl b) Hepatic function: i) Total bilirubin ≤ 1 UNL ii) Aspartate aminotransferase (ASAT) (Serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine amino transferase (ALAT) (Serum glutamic-pyruvic transaminase \[SGPT\]) ≤ 2.5 UNL iii) Alkaline phosphatase ≤ 5 UNL iv) Participants with ASAT and/or ALAT \> 1.5 x UNL associated with alkaline phosphatase \> 2.5 x UNL are not eligible for the study. c) Renal function: i) Creatinine ≤ 175 µmol/L (2 mg/dL) ii) If creatinine was 140 - 175 μmol/L, the calculated creatinine clearance should be ≥ 60 mL/min. * Complete staging work-up within 3 months prior to registration. All participants had bilateral mammography, chest X-ray (posterioanterior \[PA\] and lateral) and/or computerized tomography (CT) and/or magnetic resonance imaging (MRI), abdominal ultrasound and/or CT scan and/or MRI, and bone scan. In cases of positive bone scans, bone X-ray evaluation was mandatory to rule out the possibility of metastatic bone scan positivity. Other tests may be performed as clinically indicated. * Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of childbearing potential. * An audiology assessment with normal results was to be performed within 4 weeks of registration. This was only for those centers who had selected cisplatin as their platinum salt of choice for the BCIRG 006 study. Exclusion criteria: * Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy). * Prior anthracycline therapy, taxoids (paclitaxel, docetaxel) or platinum salts for any malignancy. * Prior radiation therapy for breast cancer. * Bilateral invasive breast cancer. * Pregnant, or lactating participants. Participants of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment (chemotherapy and tamoxifen therapy) and must had negative urine or serum pregnancy test within 7 days prior to registration. * Any T4 or N2 or known N3 or M1 breast cancer. * Pre-existing motor or sensory neurotoxicity of a severity ≥ grade 2 by National Cancer Institute (NCI) criteria. * Cardiac disease that would preclude the use of doxorubicin, docetaxel and Herceptin: 1. any documented myocardial infarction 2. angina pectoris that required the use of antianginal medication 3. any history of documented congestive heart failure 4. Grade 3 or Grade 4 cardiac arrhythmia (NCI Common Terminology Criteria \[CTC\], version 2.0) 5. clinically significant valvular heart disease 6. participants with cardiomegaly on chest x-ray or ventricular hypertrophy on ECG, unless they demonstrate by MUGA scan within the past 3 months that the LVEF was ≥ the lower limit of normal for the radiology facility; 7. participants with poorly controlled hypertension i.e. diastolic greater than 100 mm/Hg. (Participants who were well controlled on medication were eligible for entry) 8. participants who currently received medications (digitalis, beta-blockers, calcium channel-blockers, etc) that altered cardiac conduction, if these medications were administered for cardiac arrhythmia, angina or congestive heart failure. If these medications were administered for other reasons (ie hypertension), the participant was eligible. * Other serious illness or medical condition: 1. history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent 2. active uncontrolled infection 3. active peptic ulcer, unstable diabetes mellitus 4. impaired hearing (only for those participants treated at centers who had selected cisplatin as their platinum salt of choice) * Past or current history of neoplasm other than breast carcinoma, except for: 1. curatively treated non-melanoma skin cancer 2. in situ carcinoma of the cervix 3. other cancer curatively treated and with no evidence of disease for at least 10 years 4. ipsilateral DCIS of the breast 5. lobular carcinoma in-situ (LCIS) of the breast * Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. Participants must had discontinued these agents prior to randomization. * Chronic treatment with corticosteroids unless initiated \> 6 months prior to study entry and at low dose (≤ 20 mg methylprednisolone or equivalent). * Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to randomization. * Definite contraindications for the use of corticosteroids. * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry. * Concurrent treatment with any other anti-cancer therapy. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
- healthy Volunteers
- false
- maximum Age
- 70 Years
- minimum Age
- 18 Years
- sex
- FEMALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
- intervention Names
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Docetaxel
- label
- Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)
- type
- EXPERIMENTAL
- description
- Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
- intervention Names
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Docetaxel
- Drug: Herceptin
- label
- AC followed by Docetaxel + Herceptin (AC→TH)
- type
- EXPERIMENTAL
- description
- Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
- intervention Names
- Drug: Docetaxel
- Drug: Herceptin
- Drug: Carboplatin
- label
- Docetaxel + Carboplatin + Herceptin (TCH)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- AC followed by Docetaxel + Herceptin (AC→TH)
- Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)
- name
- Doxorubicin
- type
- DRUG
- arm Group Labels
- AC followed by Docetaxel + Herceptin (AC→TH)
- Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)
- name
- Cyclophosphamide
- type
- DRUG
- arm Group Labels
- AC followed by Docetaxel + Herceptin (AC→TH)
- Docetaxel + Carboplatin + Herceptin (TCH)
- Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)
- name
- Docetaxel
- other Names
- Taxotere
- type
- DRUG
- arm Group Labels
- AC followed by Docetaxel + Herceptin (AC→TH)
- Docetaxel + Carboplatin + Herceptin (TCH)
- name
- Herceptin
- other Names
- Trastuzumab
- type
- DRUG
- arm Group Labels
- Docetaxel + Carboplatin + Herceptin (TCH)
- name
- Carboplatin
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 3222
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Disease Free Survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.
- measure
- Percentage of Participants With Disease Free Survival at 5 Years
- time Frame
- From randomization until relapse or death or up to 5 years
- secondary Outcomes
- description
- Disease free survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.
- measure
- Percentage of Participants With Disease Free Survival at 10 Years
- time Frame
- From randomization until relapse or death or up to 10 years
- description
- Overall survival of the participants was measured from the date of randomization up to the date of death due to any cause. Overall survival was estimated using the Kaplan-Meier method.
- measure
- Overall Survival- Percentage of Participants Who Survived at 10 Years
- time Frame
- From randomization until death or up to 10 years
Full study description
- brief Summary
- Primary objective: * Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin. Secondary objective: * Compare overall survival of participants treated with these regimens. * Compare the toxic effects (including cardiac) of these regimens in these participants. * Compare quality of life of participants treated with these regimens. * Compare pathologic and molecular markers for predicting efficacy of these regimens in these participants. * For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with fluorescence in situ hybridization in predicting outcome in participants treated with these regimens.
Source references
- references
- citation
- Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
- pmid
- 21991949
- type
- BACKGROUND
- citation
- Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pinter T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bee V, Santana MJ, Miller DP, Lalla D, Slamon DJ; Translational Research in Oncology BCIRG 006 Trial Investigators. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013;18(7):812-8. doi: 10.1634/theoncologist.2013-0091. Epub 2013 Jun 28.
- pmid
- 23814044
- type
- BACKGROUND
- citation
- Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19.
- pmid
- 23420271
- type
- BACKGROUND
- citation
- Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28.
- pmid
- 21189395
- type
- BACKGROUND
- citation
- Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res. 2015 May 1;21(9):2065-74. doi: 10.1158/1078-0432.CCR-14-2993. Epub 2015 Feb 3.
- pmid
- 25649019
- type
- BACKGROUND
- citation
- Blasco A, Lopez-Tarruella S, Urruticoechea A, Carrasco E, Spera G, Martin M, Bermejo B, Chap L, Ruiz-Borrego M, Crown J, Garcia-Saenz JA, Chan A, Guerrero-Zotano A, Semiglazov V, Calvo L, Pienkowski T, Herranz J, Slamon D. Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials. Oncologist. 2025 Sep 1;30(9):oyaf263. doi: 10.1093/oncolo/oyaf263.
- pmid
- 40838872
- type
- DERIVED
- citation
- Garcia-Saenz JA, Spera G, Pollan M, Bermejo B, Ruiz-Borrego M, Chan A, Martin M, Guerrero-Zotano A, Calvo L, Rodriguez-Lescure A, Marin M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio O, Bezares S, Slamon D. Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. Int J Cancer. 2025 Aug 15;157(4):709-721. doi: 10.1002/ijc.35432. Epub 2025 Apr 10.
- pmid
- 40207789
- type
- DERIVED
- citation
- Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693.
- pmid
- 27573653
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-4f6f41b613ae2ba230fb
- requested nct id
- NCT00021255
- primary nct id
- NCT00021255
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- payload sha256
- d31d11a6d046b96d4ec42006c68175e4c27ee9f161548dba4f5ae116a625312d
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-4f6f41b613ae2ba230fb
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00021255
- occurrences
- context exact
- .001) and an increase in the 10-year OS rate from 75.2% to 84%.[<a href="#cit/section_6.132">132</a>] </li></ul></div></li><li>In the <a href="/clinicaltrials/NCT00021255">BCIRG-006</a> trial (NCT00021255), 3,222 women with early-stage HER2-overexpressing breast cancer were randomly assigned to receive AC followed by docetaxel (
- end
- 417878
- exact text
- NCT00021255
- start
- 417867
- context exact
- ear OS rate from 75.2% to 84%.[<a href="#cit/section_6.132">132</a>] </li></ul></div></li><li>In the <a href="/clinicaltrials/NCT00021255">BCIRG-006</a> trial (NCT00021255), 3,222 women with early-stage HER2-overexpressing breast cancer were randomly assigned to receive AC followed by docetaxel (AC-T), AC followed by docetaxel pl
- end
- 417912
- exact text
- NCT00021255
- start
- 417901
- context exact
- and 2.5% in arm C, (trastuzumab concomitant with paclitaxel).</li><li>In the<a href="/clinicaltrials/NCT00768092"> AVENTIS-TAX-GMA-302</a> (BCIRG 006) trial (NCT00021255), clinically symptomatic cardiac events were detected in 0.38% of patients in the doxorubicin and cyclophosphamide (AC)/docetaxel (AC-D) arm, 1.87% of patients
- end
- 516234
- exact text
- NCT00021255
- start
- 516223
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:35.419733+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
- source title
- Breast Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: April 25, 2025
- datetime
- 2025-04-25T12:00:00Z
- display
- April 25, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-9e9ac18c5beee1cb7407
- requested nct id
- NCT00021255
- primary nct id
- NCT00021255
- source kind
- fda_spl_label
- source record id
- bdc7c85f-c38e-493d-90c8-105bef6212a9
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- e207b478eebfa33b5807b32d129119712da9535074e937dfbeca5c8736f1b7d7
- payload
- application numbers
- BLA761106
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-9e9ac18c5beee1cb7407
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00021255
- occurrences
- context exact
- atients who discontinued intravenous trastuzumab due to cardiac toxicity at 12.6 months median duration of follow-up was 2.6% (44/1678). In the BCIRG006 study (NCT00021255), a total of 2.9% (31/1056) of patients in the TCH arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patient
- end
- 4776
- exact text
- NCT00021255
- start
- 4765
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/38/warnings_and_cautions/0
- source kind
- fda_spl_label
- source record id
- bdc7c85f-c38e-493d-90c8-105bef6212a9
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 696eca008a49b1efc0e07565f6430a8c2101f3ca8954ca3ae7f93ebaf823da13
- spl effective time
- 20260529
- spl set id
- ebf30894-41cf-480c-8bc3-56f592a13813
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b9b52407db38e39437f0
- requested nct id
- NCT00768092
- primary nct id
- NCT00021255
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- payload sha256
- 4f4df3c1baa014e631090f4b970addc91dc1932c9f9449a67a710b68d20265aa
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b9b52407db38e39437f0
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00768092
- occurrences
- context exact
- astuzumab), 3.5% in arm B (trastuzumab after paclitaxel), and 2.5% in arm C, (trastuzumab concomitant with paclitaxel).</li><li>In the<a href="/clinicaltrials/NCT00768092"> AVENTIS-TAX-GMA-302</a> (BCIRG 006) trial (NCT00021255), clinically symptomatic cardiac events were detected in 0.38% of patients in the doxorubicin and cycl
- end
- 516177
- exact text
- NCT00768092
- start
- 516166
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:35.419733+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
- source title
- Breast Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: April 25, 2025
- datetime
- 2025-04-25T12:00:00Z
- display
- April 25, 2025
Preserved source evidence · Not medical advice